Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-12-16

Clinical Trial Update: Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating azacitidine for relapsed or refractory multiple myeloma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AZACITIDINE (AZACITIDINE)

Snippet

Sponsor: Bayside Health | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED